Document   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 22, 2018

PFIZER INC. 

(Exact name of registrant as specified in its charter)

[DATA_TABLE_REMOVED]

Registrant's telephone number, including area code: 

(212) 733-2323  

Not Applicable 

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  

 Emerging growth company [ ]  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. [ ] 

 Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 22, 2018, the Board of Directors of Pfizer Inc. (the “Company”) elected Dr. Albert Bourla, who is the Company’s Chief Operating Officer, to serve as a member of the Company’s Board of Directors, effective immediately. 

Dr. Bourla will not receive any additional compensation as a result of his election to the Board of Directors.

The press release, dated February 23, 2018, announcing the election of Dr. Bourla is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits. 

(d) Exhibits  

Exhibit No.Description 

99.1Press Release of Pfizer Inc. dated February 23, 2018 

EXHIBIT INDEX

Exhibit No.Description

99.1Press Release of Pfizer Inc. dated February 23, 2018

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

[DATA_TABLE_REMOVED]